L-Thyroxine

• Description:

  L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine, T3) from L-Thyroxine (T4) [1].

• Product Name Alternative:

  Levothyroxine; T4

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Endogenous Metabolite; Thyroid Hormone Receptor

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research:

  Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/l-thyroxine.html

• Purity:

  99.49

• Solubility:

  1M NaOH : 5 mg/mL (ultrasonic; warming; adjust pH to 11 with NaOH; heat to 60°C) |DMSO : 233.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  N[C@@H](CC1=CC(I)=C(C(I)=C1)OC2=CC(I)=C(O)C(I)=C2)C(O)=O

• Molecular Formula:

  C15H11I4NO4

• Molecular Weight:

  776.87

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65 (3) :317-323.|[2]Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2 (4) :144-149.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Human Endogenous Metabolite

• Citation 01:

  Cell Rep Med. 2023 Jun 20;4 (6) :101061.|Dis Model Mech. 2024 Aug 14:dmm.050748.|EMBO J. 2024 Aug;43 (15) :3090-3115.|Mol Brain. 2021 Jan 27;14 (1) :25.|Nat Immunol. 2024 Apr;25 (4) :659-670.|Sci Rep. 2022 Jul 4;12 (1) :11259.|Stem Cell Rev Rep. 2021 Jun;17 (3) :999-1013.|J Drug Deliv Sci Technol. 2023 Sep 28, 105008.|Ther Deliv. 2025 Oct 30:1-15.

• CAS Number:

  [51-48-9]